205 related articles for article (PubMed ID: 18287338)
1. The utility of body FDG PET in staging primary central nervous system lymphoma.
Mohile NA; Deangelis LM; Abrey LE
Neuro Oncol; 2008 Apr; 10(2):223-8. PubMed ID: 18287338
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Yield of Body CT and Whole-Body FDG PET/CT for Initial Systemic Staging in Patients With Suspected Primary CNS Lymphoma: A Systematic Review and Meta-Analysis.
Park HY; Suh CH; Huang RY; Guenette JP; Kim HS
AJR Am J Roentgenol; 2021 May; 216(5):1172-1182. PubMed ID: 32812800
[No Abstract] [Full Text] [Related]
3. Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study.
Bertaux M; Houillier C; Edeline V; Habert MO; Mokhtari K; Giron A; Bergeret S; Hoang-Xuan K; Cassoux N; Touitou V; Choquet S; Soussain C; Kas A
J Neurooncol; 2020 Jun; 148(2):343-352. PubMed ID: 32405997
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis.
Zou Y; Tong J; Leng H; Jiang J; Pan M; Chen Z
Oncotarget; 2017 Jun; 8(25):41518-41528. PubMed ID: 28514747
[TBL] [Abstract][Full Text] [Related]
5. Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma.
Gupta M; Gupta T; Purandare N; Rangarajan V; Puranik A; Moiyadi A; Shetty P; Epari S; Sahay A; Mahajan A; Janu A; Bagal B; Menon H; Kannan S; Krishnatry R; Sastri GJ; Jalali R
CNS Oncol; 2019 Dec; 8(4):CNS46. PubMed ID: 31779471
[No Abstract] [Full Text] [Related]
6.
Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
[TBL] [Abstract][Full Text] [Related]
7. Primary Central Nervous System Lymphoma: Diagnostic Yield of Whole-Body CT and FDG PET/CT for Initial Systemic Imaging.
Suh CH; Kim HS; Park JE; Jung SC; Choi CG; Kim SJ
Radiology; 2019 Aug; 292(2):440-446. PubMed ID: 31237497
[TBL] [Abstract][Full Text] [Related]
8. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.
Blum RH; Seymour JF; Wirth A; MacManus M; Hicks RJ
Clin Lymphoma; 2003 Jun; 4(1):43-9. PubMed ID: 12837154
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography.
Kim HO; Kim JS; Kim SO; Chae SY; Oh SJ; Seo M; Lee SH; Oh JS; Ryu JS; Huh JR; Kim JH
Medicine (Baltimore); 2020 May; 99(20):e20140. PubMed ID: 32443328
[TBL] [Abstract][Full Text] [Related]
10. Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings.
Kawai N; Okubo S; Miyake K; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T
Ann Nucl Med; 2010 Jun; 24(5):335-43. PubMed ID: 20379859
[TBL] [Abstract][Full Text] [Related]
11. Utility of brain FDG-PET in primary CNS lymphoma.
Mohile NA; Deangelis LM; Abrey LE
Clin Adv Hematol Oncol; 2008 Nov; 6(11):818-20, 840. PubMed ID: 19194366
[TBL] [Abstract][Full Text] [Related]
12. Quantitative and Visual Characteristics of Primary Central Nervous System Lymphoma on
Liu D; Kong Z; Wang Y; Chen W; Wang Y; Chen W; Liu L; Dang Y; Ma W; Wang Y; Cheng X
Interdiscip Sci; 2019 Jun; 11(2):300-306. PubMed ID: 31264053
[TBL] [Abstract][Full Text] [Related]
13. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Yield of Extensive Systemic Staging Including Whole-body 18F-fluoro-deoxy-glucose Positron Emission Tomography With or Without Computed Tomography in Patients With Primary Central Nervous System Lymphoma: Systematic Review and Meta-analysis.
Gupta T; Manjali JJ; Kannan S; Purandare N; Rangarajan V
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e836-e845. PubMed ID: 32712087
[TBL] [Abstract][Full Text] [Related]
15. The incidence of secondary central nervous system involvement in patients with non-Hodgkin's lymphoma as detected by 18F-FDG PET/CT.
Akkas BE; Vural GU
Nucl Med Commun; 2013 Jan; 34(1):50-6. PubMed ID: 23111376
[TBL] [Abstract][Full Text] [Related]
16. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up.
Palmedo H; Urbach H; Bender H; Schlegel U; Schmidt-Wolf IG; Matthies A; Linnebank M; Joe A; Bucerius J; Biersack HJ; Pels H
Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):164-8. PubMed ID: 16220304
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.
Yamaguchi S; Hirata K; Kobayashi H; Shiga T; Manabe O; Kobayashi K; Motegi H; Terasaka S; Houkin K
Ann Nucl Med; 2014 Aug; 28(7):603-9. PubMed ID: 24743915
[TBL] [Abstract][Full Text] [Related]
18. Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough?
O'Neill BP; Dinapoli RP; Kurtin PJ; Habermann TM
J Neurooncol; 1995; 25(1):67-71. PubMed ID: 8523091
[TBL] [Abstract][Full Text] [Related]
19. [Usefulness and limitation of FDG-PET in the diagnosis of primary central nervous system lymphoma].
Kawai N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
No Shinkei Geka; 2013 Feb; 41(2):117-26. PubMed ID: 23378387
[TBL] [Abstract][Full Text] [Related]
20. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
Ngeow JYY; Quek RHH; Ng DCE; Hee SW; Tao M; Lim LC; Tan YH; Lim ST
Ann Oncol; 2009 Sep; 20(9):1543-1547. PubMed ID: 19474116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
